PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/releaseid=259822 .
Dr Fintan Walton, CEO, PharmaVentures commented, PharmaVentures are delighted to have supported Helsinn in the strategic divestment of its pharmaceutical API manufacturing business. This
success was achieved despite the current difficult economic environment and demonstrates why we are recognised as leaders in deal making. It also helps ensure an ongoing future for the
Helsinn Chemicals Ireland business and its employees under the new ownership of the Medinco C.F.M. Group.
Please contact:
Dr Fintan Walton, CEO
PharmaVentures Ltd
+44 (0) 1865 784 187
About PharmaVentures Ltd
PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The
Company'ss core business is the provision of tailored advisory and transaction services to the Life Science industry, with additional deal making support provided through the
PharmaDeals's174; range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews
and deal making trends through the world'ss first online pharmaceutical television show www.pharmatelevision.com. Now in its 16th year
PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With
offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.
For further information about PharmaVentures Ltd please contact:
Lisa Holloway
Marketing
+44 (0) 1865 784 177